The Algenpantucel-L vaccine consisting of irradiated, allogeneic pancreatic tumor cells stably expressing alpha-1,3-galactosyltransferase 2 (A3GALT2), a glycosylating enzyme that mainly targets lipids and extracellular proteins, turned out to be the most promising candidate for a PDAC-targeting vaccine [209]. Here, A3GALT2 is linked to pancreatic neoplasm.